Prime Medicine was founded with a goal of transforming the lives of patients with debilitating diseases through the application of its groundbreaking Prime Editing platform and technology. The company uses Prime Editing, a next-generation gene editing approach that aims to address the genetic cause of disease and potentially provide patients with long-lasting cures. Prime Editing searches to find the precise place in the genome to edit and replaces the faulty DNA segment with a correct copy.
Prime Medicine is powered by a versatile, precise, efficient, and broad gene editing technology developed in the lab of Dr. David R. Liu at the Broad Institute of MIT and Harvard. The company is committed to delivering a new class of differentiated one-time curative genetic therapies to address the widest spectrum of diseases. Its vision is to change how disease is treated by providing potentially lifelong benefits to patients and shaping the future of gene editing.